Kim Dong Hyun, Seo Jeongmin, Shin Dong-Yeop, Koh Youngil, Hong Junshik, Kim Inho, Yoon Sung-Soo, Byun Ja Min
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Blood Res. 2022 Dec 31;57(4):264-271. doi: 10.5045/br.2022.2022194. Epub 2022 Dec 1.
Allogeneic hematopoietic stem cell transplantation (alloSCT) is the sole curative option for myelofibrosis (MF). However, it is unknown as to which of the two, myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC), is a better preconditioning regimen.
Twenty-five patients with MF were treated with alloSCT, 12 of whom underwent RIC. Baseline characteristics, response to alloSCT, adverse events, including graft-versus-host disease (GVHD), and survival outcomes were reviewed.
There was no difference in the neutrophil engraftment rate and time to engraftment between MAC vs. RIC. The time to platelet engraftment was significantly longer in the MAC group (median, 112.8 vs. 28.8 days for MAC vs. RIC, respectively, =0.049). RIC was more advantageous in terms of achieving complete chimerism (38.5% vs. 83.3%, =0.041). The incidence of acute GVHD was 84.6% (11 of 13) and 58.3% (7 of 12) in the MAC and RIC groups, respectively. The cumulative incidence of grade III‒IV acute GVHD was significantly higher in the MAC group than in the RIC group (=0.03). No significant differences were observed in progression-free and overall survival. The 17-month probability of progression-free survival was 38.4% [95% confidence interval (CI), 19.3‒76.5] vs. 47.6% (95% CI, 25.7‒88.2) (=0.21), and that of overall survival was 53.8% (95% CI, 32.5‒89.1) vs. 48.6% (95% CI, 26.8‒88.3) (=0.85) for MAC vs. RIC, respectively.
RIC offers a significant advantage over MAC, even in younger patients with MF undergoing alloSCT, in terms of cell engraftment, rate of complete chimerism achievement, and incidence of acute GVHD.
异基因造血干细胞移植(alloSCT)是骨髓纤维化(MF)的唯一治愈选择。然而,清髓性预处理(MAC)和减低强度预处理(RIC)这两种预处理方案哪种更好尚不清楚。
25例MF患者接受了alloSCT治疗,其中12例接受了RIC。回顾了患者的基线特征、对alloSCT的反应、不良事件(包括移植物抗宿主病(GVHD))和生存结局。
MAC组和RIC组之间的中性粒细胞植入率和植入时间无差异。MAC组的血小板植入时间明显更长(中位数,MAC组为112.8天,RIC组为28.8天,P=0.049)。在实现完全嵌合体方面,RIC更具优势(分别为38.5%和83.3%,P=0.041)。MAC组和RIC组的急性GVHD发生率分别为84.6%(13例中的11例)和58.3%(12例中的7例)。MAC组III-IV级急性GVHD的累积发生率显著高于RIC组(P=0.03)。无进展生存期和总生存期无显著差异。MAC组和RIC组的17个月无进展生存率分别为38.4%[95%置信区间(CI),19.3-76.5]和47.6%(95%CI,25.7-88.2)(P=0.21),总生存率分别为53.8%(95%CI,32.5-89.1)和48.6%(95%CI,26.8-88.3)(P=0.85)。
即使在接受alloSCT的年轻MF患者中,RIC在细胞植入、完全嵌合体实现率和急性GVHD发生率方面也比MAC具有显著优势。